OptiBiotix inks licence agreement with Taiwanese probiotics outfit

10th Sep 2018 09:12

(Sharecast News) - OptiBiotix Health has inked a non-exclusive licence agreement for its cholesterol and blood pressure-reducing LPLDL products with Taiwanese probiotics outfit Bened Biomedical.As part of the three-year agreement, which comes about a year after the AIM-listed firm signed an agreement with Bendel, Bened will produce, package, promote, market, and commercialise products containing OptiBiotix's LPLDL strainOptiBiotix reached a somewhat similar licensing deal for its cholesterol-lowering bacteria with an unnamed US firm just last week, creating the opportunity for multiple six and seven-figure payments for the firm.The group expects the Taiwanese supplements market to grow 27% by 2021.OptiBiotix's commercial director Per Rehne said the deal would enhance the firm's presence in the Asia-Pacific region and allow it to "offer multiple product solutions" through its partnerships with consumer health and pharma companies.Elsewhere, OptiBiotix revealed it had appointed Sean Christie, former finance director of FTSE 100 chemical company Croda, as its newest non-executive director.As of 0910 BST, OptiBiotix shares had picked up 1.19% to 103.21p.